| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, which are essential enzymes for bacterial DNA replication, transcription, repair, and recombination. Ciprofloxacin-13C3,¹⁵N monohydrochloride is a labeled standard and has no independent antibacterial activity.
|
|---|---|
| ln Vitro |
Compounds labeled with stable or radioactive isotopes can accurately track and quantify individual atoms in metabolic pathways. Stable isotopes generally do not change molecular properties, but may slightly affect metabolic dynamics; radioactive isotopes may interfere with cells. Labeling can distinguish endogenous and exogenous metabolites, reduce false positives, and is beneficial for quantification and reconstruction of metabolic pathways [2]. In cell culture or enzyme reactions, the use of isotope labels can accurately control concentration and exposure time, making it easier to study metabolic reactions and enzyme activities. Through stable isotope-resolved metabolomics (SIRM), cellular metabolic networks can be studied, key metabolic nodes and regulatory mechanisms can be identified, and targets can be provided for compound development. Isotope-labeled compounds can be used in competition binding experiments to evaluate the affinity and binding kinetics of compounds with receptors, which helps optimize the design. Stable isotope labels are used as internal standards in mass spectrometry analysis to improve analytical accuracy and reproducibility and reduce matrix effect interference [3].
Ciprofloxacin-13C3,¹⁵N monohydrochloride does not have an independent in vitro antibacterial activity; it is a labeled internal standard. Ciprofloxacin (the non-labeled compound) shows broad-spectrum antibacterial activity. |
| ln Vivo |
Isotope labels can non-invasively track the distribution, transformation, and clearance of compounds and their metabolites in the body through techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR), which is beneficial for the study of drug metabolism dynamics (ADME). Isotope labeling can reveal specific steps in the metabolic pathway. Direct use of compounds with stable isotope labels at specific positions in human or animal models can also help verify drug mechanisms and evaluate unexpected side effects, improving the accuracy and efficiency of clinical research [3].
Ciprofloxacin-13C3,¹⁵N monohydrochloride does not have an independent in vivo activity as an internal standard; it is used for analytical purposes. |
| Enzyme Assay |
General cell-free protocol for assessing binding to DNA gyrase: This is not relevant for the labeled standard. For ciprofloxacin, the target is DNA gyrase. A generic protocol involves the use of a DNA supercoiling assay. The assay uses E. coli DNA gyrase (GyrA and GyrB subunits, 10 nM), a relaxed pBR322 DNA substrate (0.5 ug), ATP (1 mM), and varying concentrations of ciprofloxacin (0.01-100 uM) in a reaction buffer (35 mM Tris-HCl, pH 7.5, 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 6.5 mM spermidine, 0.1 mg/mL BSA, 0.1 mg/mL tRNA). The reaction is incubated at 37degC for 60 minutes and then stopped by adding SDS and proteinase K. The DNA products are separated by agarose gel electrophoresis, and the supercoiled and relaxed DNA forms are visualized by ethidium bromide staining. The IC₅0 for inhibiting DNA supercoiling is calculated.
|
| Animal Protocol |
A general protocol for the analytical use of Ciprofloxacin-13C3,¹⁵N monohydrochloride as an internal standard: Biological samples (plasma, urine, or tissue homogenates) are spiked with a fixed concentration of Ciprofloxacin-13C3,¹⁵N monohydrochloride (e.g., 100 ng/mL). The samples are processed by protein precipitation with acetonitrile (containing 0.1% formic acid) or by solid-phase extraction (SPE). After centrifugation, the supernatant is injected into the LC-MS/MS system. The mass spectrometer is operated in positive electrospray ionization mode (ESI+). The precursor-to-product ion transitions for ciprofloxacin and ciprofloxacin-13C3,¹⁵N are monitored. The m/z of the labeled compound is higher by 4 Da due to the isotopic labels. The calibration curve is constructed by plotting the peak area ratio of ciprofloxacin to the internal standard against the known concentrations of ciprofloxacin. The concentration of ciprofloxacin in the unknown samples is determined by interpolation.
|
| ADME/Pharmacokinetics |
General protocol for the pharmacokinetic analysis of ciprofloxacin using Ciprofloxacin-13C3,¹⁵N monohydrochloride as an internal standard: Male Sprague-Dawley rats are administered a single oral dose of ciprofloxacin (10, 20, or 40 mg/kg) or an intravenous dose (5 mg/kg). Blood samples are collected at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose. The blood samples are centrifuged to obtain plasma. An aliquot of plasma (50 uL) is mixed with a fixed concentration of Ciprofloxacin-13C3,¹⁵N monohydrochloride (e.g., 100 ng/mL) in a microtube. The proteins are precipitated by adding acetonitrile (150 uL) containing 0.1% formic acid. The mixture is vortexed and centrifuged at 13,000 rpm for 10 minutes. The supernatant (5 uL) is injected into the LC-MS/MS system. The concentrations of ciprofloxacin in the plasma samples are calculated based on the ratio of the peak area of ciprofloxacin to that of the internal standard. Non-compartmental analysis is performed to calculate the PK parameters: Cmax, Tmax, AUC0₋ₜ, AUC0₋∞, elimination half-life (t½), clearance (CL/F), and volume of distribution (Vd/F). Urine samples are also analyzed to determine the fraction excreted unchanged.
|
| References | |
| Additional Infomation |
Ciprofloxacin-13C3,¹⁵N monohydrochloride is a stable isotope-labeled internal standard of ciprofloxacin hydrochloride. The molecular formula is C14¹3C3H1₉ClFN2¹⁵NO3, and the molecular weight is 371.77. The compound is the ¹3C and ¹⁵N labeled form of ciprofloxacin hydrochloride. The labeled compound is used for analytical method development, method validation, and quality control applications. Ciprofloxacin (the non-labeled compound) is a broad-spectrum fluoroquinolone antibiotic used to treat various bacterial infections, including urinary tract infections, respiratory tract infections, skin and soft tissue infections, and gastrointestinal infections. Ciprofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV.
|
| Molecular Formula |
C1413C3H19CLFN215NO3
|
|---|---|
| Molecular Weight |
371.77
|
| Exact Mass |
371.116
|
| CAS # |
2483830-12-0
|
| PubChem CID |
171370177
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
571
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC1[15N]2[13CH]=[13C](C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)[13C](=O)O.Cl
|
| InChi Key |
DIOIOSKKIYDRIQ-SBKGTBHUSA-N
|
| InChi Code |
InChI=1S/C17H18FN3O3.ClH/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24;/h7-10,19H,1-6H2,(H,23,24);1H/i9+1,12+1,17+1,21+1;
|
| Chemical Name |
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;hydrochloride
|
| Synonyms |
Bay-09867-13C3,15N monohydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 12.5 mg/mL (33.62 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6898 mL | 13.4492 mL | 26.8984 mL | |
| 5 mM | 0.5380 mL | 2.6898 mL | 5.3797 mL | |
| 10 mM | 0.2690 mL | 1.3449 mL | 2.6898 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
